Literature DB >> 25297024

Rapid screening of rpoB and katG mutations in Mycobacterium tuberculosis isolates by high-resolution melting curve analysis.

M Haeili, A I Fooladi, S Z Bostanabad, D D Sarokhalil, F Siavoshi, M M Feizabadi1.   

Abstract

BACKGROUND: Early detection of multidrug-resistant tuberculosis (MDR-TB) is essential to prevent its transmission in the community and initiate effective anti-TB treatment regimen.
MATERIALS AND METHODS: High-resolution melting curve (HRM) analysis was evaluated for rapid detection of resistance conferring mutations in rpoB and katG genes. We screened 95 Mycobacterium tuberculosis clinical isolates including 20 rifampin resistant (RIF-R), 21 isoniazid resistant (INH-R) and 54 fully susceptible (S) isolates determined by proportion method of drug susceptibility testing. Nineteen M. tuberculosis isolates with known drug susceptibility genotypes were used as references for the assay validation. The nucleotide sequences of the target regions rpoB and katG genes were determined to investigate the frequency and type of mutations and to confirm HRM results.
RESULTS: HRM analysis of a 129-bp fragment of rpoB allowed correct identification of 19 of the 20 phenotypically RIF-R and all RIF-S isolates. All INH-S isolates generated wild-type HRM curves and 18 out of 21 INH-R isolates harboured any mutation in 109-bp fragment of katG exhibited mutant type HRM curves. However, 1 RIF-R and 3 INH-R isolates were falsely identified as susceptible which were confirmed for having no mutation in their target regions by sequencing. The main mutations involved in RIF and INH resistance were found at codons rpoB531 (60% of RIF-R isolates) and katG315 (85.7% of INH-R isolates), respectively.
CONCLUSION: HRM was found to be a reliable, rapid and low cost method to characterise drug susceptibility of clinical TB isolates in resource-limited settings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25297024     DOI: 10.4103/0255-0857.142245

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  6 in total

1.  Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.

Authors:  Siavash J Valafar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis using TaqMan Allelic Discrimination.

Authors:  Davood Darban-Sarokhalil; Mohammad J Nasiri; Abbas A I Fooladi; Parvin Heidarieh; Mohammad M Feizabadi
Journal:  Osong Public Health Res Perspect       Date:  2016-04-06

3.  Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates of Mycobacterium tuberculosis by high-resolution melting analysis.

Authors:  Mehrandokht Sirous; Azar Dokht Khosravi; Mohammad Reza Tabandeh; Shokrollah Salmanzadeh; Nazanin Ahmadkhosravi; Sirus Amini
Journal:  Infect Drug Resist       Date:  2018-10-18       Impact factor: 4.003

4.  The Value of the inhA Mutation Detection in Predicting Ethionamide Resistance Using Melting Curve Technology.

Authors:  Yanhua Song; Guirong Wang; Qiang Li; Rongmei Liu; Liping Ma; Qi Li; Mengqiu Gao
Journal:  Infect Drug Resist       Date:  2021-01-29       Impact factor: 4.003

5.  Rapid Identification of Drug-Resistant Tuberculosis Genes Using Direct PCR Amplification and Oxford Nanopore Technology Sequencing.

Authors:  Kaishun Zhao; Chunlin Tu; Wei Chen; Haiying Liang; Wenjing Zhang; Yilei Wang; Ye Jin; Jianrong Hu; Yameng Sun; Jun Xu; Yanfang Yu
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-03-28       Impact factor: 2.471

6.  Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using Real-Time PCR.

Authors:  Leyla Sahebi; Khalil Ansarin; Amir Monfaredan; Safar Farajnia; Seiran Nili; Majid Khalili
Journal:  Jundishapur J Microbiol       Date:  2016-04-16       Impact factor: 0.747

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.